Evaluation of the sensitivities of six triple-negative breast cancer (TNBC) cell lines to 23 different PI3K/AKT/mTOR inhibitors or to a MEK inhibitor (trametinib). Dataset 1 of 2: GR values. - Dataset (ID:20364)
Download: Excel (XLSX), Comma-separated (CSV)
Cell line | Drug name | Experimental replicate | Timepoint | Drug concentration | Live cell count | Average live cell count, DMSO control | Average live cell count (time = 0) | Log10(drug concentration) | GR value | Relative cell count (treatment versus DMSO) | Cell doublings (DMSO control) | Experiment name |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Hs 578T | WYE-125132 | 1 | 72 | 1.0 | 982.0 | 3529.8 | 873.1 | 0.0 | 0.060 | 0.278 | 2.015 | Hs578T WYE125132 1 |
Hs 578T | Dactolisib | 2 | 72 | 1.0 | 728.5 | 3555.0 | 624.7 | 0.0 | 0.063 | 0.205 | 2.509 | Hs578T BEZ235 2 |
HCC38 | Dactolisib | 3 | 72 | 0.1 | 1295.5 | 3265.3 | 1180.5 | -1.0 | 0.065 | 0.397 | 1.468 | HCC38 BEZ235 0 3 72 |
BT-549 | Torin1 | 3 | 72 | 0.32 | 1312.5 | 3974.5 | 1175.8 | -0.495 | 0.065 | 0.330 | 1.757 | BT549 Torin1 0 3 72 |
Hs 578T | Trametinib | 3 | 72 | 3.2 | 684.0 | 4062.0 | 571.3 | 0.505 | 0.066 | 0.168 | 2.830 | Hs578T Trametinib 3 |
HCC38 | Omipalisib | 1 | 72 | 0.32 | 1460.0 | 4389.3 | 1295.5 | -0.495 | 0.070 | 0.333 | 1.760 | HCC38 GSK458 0 1 72 |
BT-549 | Omipalisib | 2 | 72 | 0.1 | 1429.3 | 4963.8 | 1249.6 | -1.0 | 0.070 | 0.288 | 1.990 | BT549 GSK458 0 2 72 |
BT-20 | WYE-125132 | 2 | 72 | 0.1 | 1155.5 | 3613.5 | 1018.6 | -1.0 | 0.072 | 0.320 | 1.827 | BT20 WYE125132 0 2 |
BT-549 | WYE-125132 | 2 | 72 | 0.32 | 1416.8 | 4290.8 | 1249.6 | -0.495 | 0.073 | 0.330 | 1.780 | BT549 WYE125132 0 2 72 |
Hs 578T | AZD8055 | 1 | 72 | 3.2 | 1005.8 | 3514.5 | 873.1 | 0.505 | 0.073 | 0.286 | 2.009 | Hs578T AZD8055 1 |
BT-549 | AZD8055 | 3 | 72 | 0.32 | 1330.5 | 3973.3 | 1175.8 | -0.495 | 0.073 | 0.335 | 1.757 | BT549 AZD8055 0 3 72 |
Hs 578T | Trametinib | 2 | 72 | 3.2 | 745.8 | 3491.8 | 624.7 | 0.505 | 0.074 | 0.214 | 2.483 | Hs578T Trametinib 2 |
BT-549 | Torin1 | 3 | 72 | 3.2 | 1337.3 | 3974.5 | 1175.8 | 0.505 | 0.076 | 0.336 | 1.757 | BT549 Torin1 0 3 72 |
HCC38 | WYE-125132 | 3 | 72 | 0.32 | 1313.8 | 3222.8 | 1180.5 | -0.495 | 0.077 | 0.408 | 1.449 | HCC38 WYE125132 0 3 72 |
BT-20 | AZD8055 | 3 | 72 | 0.32 | 709.0 | 3441.0 | 586.9 | -0.495 | 0.077 | 0.206 | 2.552 | BT20 AZD8055 0 3 |
BT-549 | Torin1 | 1 | 72 | 3.2 | 1780.5 | 5391.5 | 1554.9 | 0.505 | 0.078 | 0.330 | 1.794 | BT549 Torin1 0 1 72 |
BT-549 | WYE-125132 | 2 | 72 | 3.2 | 1429.3 | 4290.8 | 1249.6 | 0.505 | 0.078 | 0.333 | 1.780 | BT549 WYE125132 0 2 72 |
Hs 578T | Trametinib | 2 | 72 | 1.0 | 753.3 | 3491.8 | 624.7 | 0.0 | 0.078 | 0.216 | 2.483 | Hs578T Trametinib 2 |
HCC70 | Torin2 | 2 | 72 | 0.32 | 830.0 | 2562.3 | 722.8 | -0.495 | 0.079 | 0.324 | 1.826 | HCC70 Torin2 0 2 72 |
BT-20 | Torin2 | 3 | 72 | 0.32 | 707.8 | 3225.3 | 586.9 | -0.495 | 0.079 | 0.219 | 2.458 | BT20 Torin2 0 3 |
HCC38 | Omipalisib | 2 | 72 | 0.32 | 814.8 | 3009.3 | 690.5 | -0.495 | 0.081 | 0.271 | 2.124 | HCC38 GSK458 0 2 72 |
Hs 578T | WYE-125132 | 1 | 72 | 3.2 | 1021.0 | 3529.8 | 873.1 | 0.505 | 0.081 | 0.289 | 2.015 | Hs578T WYE125132 1 |
HCC38 | Torin1 | 1 | 72 | 1.0 | 1482.8 | 4174.3 | 1295.5 | 0.0 | 0.083 | 0.355 | 1.688 | HCC38 Torin1 0 1 72 |
BT-20 | Omipalisib | 3 | 72 | 0.032 | 723.0 | 3523.0 | 586.9 | -1.49 | 0.084 | 0.205 | 2.586 | BT20 GSK458 0 3 |
BT-549 | Torin1 | 2 | 72 | 1.0 | 1461.5 | 4603.3 | 1249.6 | 0.0 | 0.087 | 0.317 | 1.881 | BT549 Torin1 0 2 72 |